UNSPSC 51433708: Riociguat

Riociguat is a stimulator of soluble guanylate cyclase. It is used to treat two forms of pulmonary hypertension: chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

UNSPSC 51433708 Riociguat, a Commodity code, shows minimal recent state and local procurement activity aligned with its pharmaceutical scope. The source records identify one opportunity nominally tagged to this code—Seminole County, Florida's June 2026 solicitation for naloxone and drug deactivation systems through an IFB with a due date of July 26, 2026—but the remaining nine recent postings span unrelated activities including vendor forums, reverse trade shows, nursing peer-support services, medical oxygen cylinder rental, engineering services, generic pharmaceuticals through cooperative purchasing, and departmental relocation notices. The single pharmaceutical-adjacent opportunity (naloxone and deactivation systems) diverges from riociguat's vasodilator scope and represents emergency-response medical supplies rather than pulmonary hypertension treatment.

Issuing bodies in the source span Florida counties (Seminole, Pinellas, Marion, Indian River, Collier, Orange), Texas municipalities and counties (Williamson, Collin, Little Rock, Richardson), and multistate cooperatives (MMCAP), with most recent postings dedicated to vendor networking events rather than formal solicitations for riociguat or related pulmonary hypertension medications. No state or local jurisdiction in the source records has posted a competitive solicitation specifically for riociguat or equivalent small-molecule pulmonary hypertension vasodilators. The code warrants watch-only status; pursue opportunities only when a state health department, county public health agency, or regional healthcare authority posts a formal RFP or RFQ explicitly naming riociguat or PAH-treatment pharmaceuticals as a line item.